Lalezari 2013.

Study characteristics
Study design	Cohort
Study setting	Setting: University of California Los Angeles and Kaiser Permanente Los Angeles Country: USA Dates: diagnosed between 2000 and 2010.
Selection of participants	People were retrospectively identified based on an electronic database query of adults with primary GBM receiving upfront TMZ and treated at the University of California Los Angeles or Kaiser Permanente Los Angeles. People whose samples were directed to the laboratory in an unselected manner were also included.
Participant characteristics	Sample size: 418 (deaths: 356) Age: median 57.6; range 22.3–90.0 years Sex: 60.8% men KPS: median NR; KPS 100: 13.9%; KPS 90: 47.6%; KPS 80: 24.6%; KPS 70: 6.2%; KPS ≤ 60: 7.2%; KPS missing: 0.5%
Tumour characteristics	GBM: 100% First diagnosis: 100% Biopsy: 9.1%; subtotal resection: 47.8%; total resection: 41.9%; NR IDH1 wild‐type: NR; IDH2 wild‐type: NR
Treatment regimen	Combination of radiotherapy and TMZ: concurrent daily radiotherapy/TMZ followed by TMZ (Stupp, n = 235), maintenance dose TMZ overlapping with radiotherapy (modified Stupp, n = 127), TMZ after radiotherapy (pre‐Stupp, n = 48).
MGMT promoter methylation tests implemented	MSP, PSQ, IHC
Dates and follow‐up	Timing of MGMT assessment: FFPE samples from initial surgery prior to any treatment Start time for follow‐up: NR; follow‐up: median 70; range 2–137 years
Notes